Cargando…
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatiti...
Autores principales: | Kieran, Jennifer Ann, Norris, Suzanne, O’Leary, Aisling, Walsh, Cathal, Merriman, Raphael, Houlihan, D., McCormick, P. Aiden, McKiernan, Susan, Bergin, Colm, Barry, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624167/ https://www.ncbi.nlm.nih.gov/pubmed/26503519 http://dx.doi.org/10.1186/s12879-015-1208-1 |
Ejemplares similares
-
Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response
por: Elsherif, Omar, et al.
Publicado: (2017) -
Milestones in the discovery of hepatitis C
por: Campollo, Octavio, et al.
Publicado: (2022) -
Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
por: Gray, Emma, et al.
Publicado: (2017) -
The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors
por: Nguyen, Linh Thuy, et al.
Publicado: (2016) -
Generic substitution of antiretrovirals: patients’ and health care providers’ opinions
por: Kieran, Jennifer A, et al.
Publicado: (2017)